BioSig Technologies issued an update to shareholders highlighting recent milestones and ongoing company developments. "January 2023 marks the one-year anniversary of redefining our product development and commercial strategies led by John Sieckhaus and Gray Fleming, respectively. During this time, we have built new sales and clinical teams, introduced new corporate and product branding, launched potentially game-changing software, secured numerous evaluations, established new research protocols, signed purchase agreements, and created a promising revenue pipeline. These are milestones never seen before at BioSig and we believe there are many more exciting ones ahead. While we are proud of the commercial progress BioSig has made over the past twelve months, 2022 proved to be a challenging year for the economy, and especially for Life Sciences companies like ours. This was reflected in our valuation. History shows us that innovative companies and technologies can prevail following economic downturns. The sharp market declines in 2000-2002 and 2008-2009 were followed by economic recoveries where new leaders emerged. We are confident that BioSig will be one of those emerging leaders based on the exciting commercial, technology and corporate activities underway in 2023’" said the company.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSGM:
- BioSig executes agreement with Bellin for acquisition of PURE EP technology
- BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology
- Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
- BioSig Technologies PURE EP featured in abstract presentation
- BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore